Medical History of Aniracetam
The multinational Swiss healthcare company Hoffmann-La Roche first created Aniracetam in the 1970s. The drug was found to positively influence the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, or AMPA, receptors that affect the speed at which nerve signals move between neurons. Due to this, some believe that the supplement can stimulate an improvement in cognitive functions in those with Alzheimer’s and other dementia-like diseases of the brain. The drug has also been claimed to provide a boost of energy and alertness to individuals, like that of a stimulant. The FDA has not approved it due to the lack of scientific information available on its safety, efficiency, and benefits.
The drug goes by several different brand names Sarpul, Memodrin, Ampamet, Referan, and Draganon.
While the FDA has not approved Aniracetam for use in treating any ailment, manufacturers promote the product for its cognitive and energy enhancing abilities. These potential benefits have not been proven in the scientific community and thus are considered unsubstantiated. The potential benefits of the drug include:
– Supporting the function of serotonin and dopamine in the brain, providing easement of depression symptoms
– An increased quality of sleep
– Better management of appetite and weight
– Improvement in mild cognitive impairment of elderly individuals
– Improved mood
– Increased blood flow and activity in the brain
– Boosts energy
– Increases mental alertness
– Increased mental focus and concentration
– Improved cognition
– Restores neural pathways damaged during brain injury
– Reduces stress
The long term safety of Aniracetam is unknown at this time due to the lack of scientific information. Clinical trials of the drug typically span a year time, and it is thus concluded to be safe for use up to a year. Mild side effects are somewhat common and include anxiety, vertigo, headaches, insomnia, irritability, nausea, diarrhea, and jitteriness.
The drug is known to negatively interact with other medications. It is not recommended to consume if an individual is also taking any antidepressants, anticonvulsants, opiates, benzodiazepines, anticoagulants, antihistamines, antipsychotics, sedatives, HIV drugs, or anesthetics.
The drug is also not recommended for use while pregnant or breastfeeding due to the unknown safety and possible reactions it may cause.
While Aniracetam is widely available as a dietary supplement, the lack of FDA approval and comparative research makes it difficult to prescribe an accurate recommended dosage for each individual. If possible, it is best to visit with a healthcare provider before deciding to use the supplement. They can help guide individuals to an appropriate dose while also preventing adverse reactions by researching the medical history and list of medications an individual may currently be on.
Alternatively, manufacturers list recommended dosage instructions on the supplement’s container, which can also be followed. But these dosage suggestions may not work depending on what the drug is being taken for. It is commonly sold as a 750 mg capsule and could be present in other combination nootropic supplements. The available clinical studies suggest a daily intake of 1,500 mg taken by mouth, with or without food.
Aniracetam exhibits potential in being a potent nootropic drug for use by individuals who suffer from cognitive decline and dementia diseases. While the FDA has not approved the drug, clinical evidence and individual reviews show it to be relatively safe for consumption for short periods of time. More research will be needed to conclusively prove its effectiveness.